MARLBOROUGH, Mass.– Ocata Therapeutics, Inc., (OTCBB:OCAT) today announced that it has been granted Advanced Therapy Medicinal Product (ATMP) designation for its RPE therapy for macular degeneration. This designation is an essential step in allowing companies to commercialize products effectively across the European Union.
Dr. Eddy Anglade, Chief Medical Officer of Ocata Therapeutics, said: “We are pleased to receive ATMP status from the EMA. We view this as an important step to further enable the development of our novel biological therapy in the EU with the aim of seeking marketing authorization approval. Additionally, we interpret this as a favorable indication for how the European regulators view our therapy.”